Columbia and Illumina Settle Patent Suit on DNA Sequencing

June 9, 2021, 3:10 PM

Columbia University and Qiagen had claimed that certain Illumina DNA-sequencing instruments infringe five patents for the technology.

  • Parties “have settled the case in principle” and asked for time to complete settlement, according to letter sent Tuesday to judge in federal court in Wilmington, Delaware
  • Patents, owned by Columbia and exclusively licensed to Qiagen, are related to using modified versions of nucleotides to sequence DNA, complaint says
  • The nucleotide analogues, as the modified versions are called, are useful in next-generation sequencing, important in the emerging field of personalized precision medicine
  • CASE: Trustees of Columbia University in the City of New York ...

To read the full article log in. To learn more about a subscription click here.